Product Information
LINZESS 72 MCG CAPSULE is a brand product labeled by Allergan, Inc., priced at $9.0108 per EA under NDC 00456120330. Its NADAC has been published 485 times since Jun 21, 2017.
FDA first approved this application on Aug 30, 2012.
Strength
72 ug/1
Manufacturer
Allergan, Inc.NDC
00456120330
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LINACLOTIDEApproval Type
New Drug (NDA)
FDA Application
NDA202811FDA Approved
8/30/2012
On Market Since
1/30/2017
Pharmacological Classes
Price Statistics
The NADAC for LINZESS 72 MCG CAPSULE has been published 485 times since Jun 21, 2017, and over the history we have for it it has declined 20.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.0108 per EA |
|---|---|
| All-time high | $18.1549 (May 14, 2025) |
| All-time low | $9.0108 (Sep 23, 2026) |
| 52-week high | $18.1394 |
| 52-week low | $9.0108 |
| Median price | $14.9289 |
| Average price | $14.6003 |
| Largest weekly change | -50.3% (Jan 14, 2026) |
| Weeks tracked | 485 |
| Tracking since | Jun 21, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the linaclotide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
linaclotide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LINZESS 72 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LINZESS 72 MCG CAPSULE, manufactured by Allergan, Inc., is $9.0108 per EA (NDC 00456120330), effective Sep 30, 2026.
How has the price of LINZESS 72 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LINZESS 72 MCG CAPSULE has declined 20.4%. It has been tracked across 485 weekly CMS publications since Jun 21, 2017.
What are the highest and lowest recorded NADAC prices for LINZESS 72 MCG CAPSULE?
Since Jun 21, 2017, the NADAC for LINZESS 72 MCG CAPSULE has ranged from a low of $9.0108 (Sep 23, 2026) to a high of $18.1549 (May 14, 2025), with a median of $14.9289 per EA.
Are there cheaper alternatives to LINZESS 72 MCG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of LINZESS 72 MCG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LINZESS 72 MCG CAPSULE?
LINZESS 72 MCG CAPSULE (NDC 00456120330) is labeled by Allergan, Inc., and CMS classifies it as a brand product.